Discovery & Development

There are many hurdles in drug development, but your chances of success increase significantly if you pay more attention to API optimization from the outset.

Clinical development is outmoded; we are witnessing serious attrition in cancer R&D. Perhaps it’s time to live and die by the mantra: “no biomarker, no trial”.

Researchers redesign existing drugs to be more biodegradable and environmentally friendly.

A digital pill submitted for regulatory approval tells caregivers if you’ve taken your medicine

Despite clinical failures in the 1990s, pharma is (cautiously) ready to try again with oral peptide formulations.

More quality control testing is needed to ensure that antibiotics don't become targets for fraudsters.

Do Brazilian wasps hold the promise of a new anticancer therapy? The answer is in the sting

Drug makers and regulators are taking steps towards transparency, but is it enough?

Lawrence (Larry) Lesko is a bioanalytical veteran with many years of academic and FDA experience under his belt.

Prescription drug abuse has already reached epidemic proportions in the US – and other countries look set to follow the dangerous trend.